St. Louis, MOWill Electronics I have spent the last 22 years of my professional life in the Security Field. My responsibilities have included Branch Office Mangement, Security System Design... I have spent the last 22 years of my professional life in the Security Field. My responsibilities have included Branch Office Mangement, Security System Design, and Account Management.
Breo Ellipta is our second asthma treatment to be approved in the United States in the past year, and now provides physicians with a range of treatment options delivered via the Ellipta inhaler to meet the needs of appropriate adult patients with differing asthma severities, Darrell Baker, senior
Date: May 01, 2015
Source: Google
GSK and Theravance's Breo Ellipta gets FDA approval to treat asthma in adults
GSK Global Respiratory Franchise senior vice-president and head Darrell Baker said: "Asthma is a variable condition and guidelines recommend a stepwise approach to treatment with the aim of achieving asthma control.
Date: May 01, 2015
Category: Health
Source: Google
Glaxo could soon tap the second half of a $6B respiratory market
We will continue to work closely with the FDA while it considers the committees recommendations and our aim is to answer any outstanding questions to enable them to make a fully informed decision, says Darrell Baker, senior vice president and head of GSK Global Respiratory Franchise.
Date: Mar 20, 2015
Category: Health
Source: Google
FDA Panel Recommends Approval Of GSK Asthma Drug For Adults But Not ...
related to Breo Ellipta for asthma. We will continue to work closely with the FDA while it considers the Committee's recommendations and our aim is to answer any outstanding questions to enable them to make a fully informed decision," said Darrell Baker, SVP & Head, GSK Global Respiratory Franchise.
Date: Mar 19, 2015
Category: Health
Source: Google
GSK receives FDA approval for Arnuity(TM) Ellipta(R) (fluticasone furoate) in the ...
Darrell Baker, SVP & Head, GSK Global Respiratory Franchise, said, "The approval of Arnuity Ellipta is an important development for GSK and our expanding respiratory portfolio. It is the first asthma treatment from our new portfolio to have gained approval in the US and enables us to begin expan
Date: Aug 20, 2014
Category: Health
Source: Google
GSK, Therevance Expect LAMA/LABA COPD Drug Filing with FDA by Year End
safety study and two replicate 12-week crossover exercise studies.We are very encouraged by the results of these initial studies for our LAMA/LABA, an important cornerstone of our broad respiratory development portfolio, comments Darrell Baker, svp respiratory portfolio optimization leader at GSK. Su
Date: Jul 02, 2012
Category: Health
Source: Google
GSK, Theravance Expect COPD Drug Filing with FDA by Year End
study, and two replicate 12-week crossover exercise studies. We are very encouraged by the results of these initial studies for our LAMA/LABA, an important cornerstone of our broad respiratory development portfolio, comments Darrell Baker, svp, respiratory portfolio optimization leader at GSK. Su